11 analysts have shared their evaluations of iRhythm Holdings (NASDAQ:IRTC) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 7 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 3 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $212.0, with a high estimate of $244.00 and a low estimate of $198.00. Experiencing a 4.03% decline, the current average is now lower than the previous average price target of $220.91.
Diving into Analyst Ratings: An In-Depth Exploration
The standing of iRhythm Holdings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Richard Newitter | Truist Securities | Lowers | Buy | $200.00 | $215.00 |
| William Plovanic | Canaccord Genuity | Lowers | Buy | $198.00 | $212.00 |
| Allen Gong | JP Morgan | Lowers | Overweight | $215.00 | $240.00 |
| Nathan Treybeck | Wells Fargo | Lowers | Overweight | $200.00 | $225.00 |
| Mike Polark | Baird | Lowers | Outperform | $200.00 | $220.00 |
| Nathan Treybeck | Wells Fargo | Raises | Overweight | $225.00 | $220.00 |
| David Saxon | Needham | Maintains | Buy | $244.00 | $244.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $210.00 | $194.00 |
| Richard Newitter | Truist Securities | Lowers | Buy | $215.00 | $230.00 |
| Mike Polark | Baird | Lowers | Outperform | $220.00 | $235.00 |
| Cecilia Furlong | Morgan Stanley | Raises | Overweight | $205.00 | $195.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to iRhythm Holdings. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of iRhythm Holdings compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of iRhythm Holdings's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into iRhythm Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on iRhythm Holdings analyst ratings.
Discovering iRhythm Holdings: A Closer Look
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Unraveling the Financial Story of iRhythm Holdings
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: iRhythm Holdings's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 30.74%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: iRhythm Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2.7%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -4.62%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): iRhythm Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.53%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 6.01, caution is advised due to increased financial risk.
The Core of Analyst Ratings: What Every Investor Should Know
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.